122 related articles for article (PubMed ID: 21542758)
21. Endoluminal brushing of blocked indwelling haemodialysis catheters.
Bel'eed K; Kumar A; Asin M; Sellars L
Nephrol Dial Transplant; 1999 Jan; 14(1):241. PubMed ID: 10052522
[No Abstract] [Full Text] [Related]
22. Comparison of intensive versus standard hemodialysis central venous catheter dysfunction protocol using rt-PA: a quality assurance initiative.
Wilson JA; Mossop P; Soroka SD; Dipchand C; Drost S; Sheehy N; Tennankore K
J Vasc Access; 2016; 17(2):143-50. PubMed ID: 26847735
[TBL] [Abstract][Full Text] [Related]
23. Comparison of alteplase and heparin in maintaining the patency of paediatric central venous haemodialysis lines: a randomised controlled trial.
Gittins NS; Hunter-Blair YL; Matthews JN; Coulthard MG
Arch Dis Child; 2007 Jun; 92(6):499-501. PubMed ID: 17068072
[TBL] [Abstract][Full Text] [Related]
24. Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients.
Shen V; Li X; Murdock M; Resnansky L; McCluskey ER; Semba CP;
J Pediatr Hematol Oncol; 2003 Jan; 25(1):38-45. PubMed ID: 12544772
[TBL] [Abstract][Full Text] [Related]
25. A longitudinal study of the repeated use of alteplase as therapy for tunneled hemodialysis catheter dysfunction.
Little MA; Walshe JJ
Am J Kidney Dis; 2002 Jan; 39(1):86-91. PubMed ID: 11774106
[TBL] [Abstract][Full Text] [Related]
26. Restoration of flow following haemodialysis catheter thrombus. Analysis of rt-PA infusion in tunnelled dialysis catheters.
Davies J; Casey J; Li C; Crowe AV; McClelland P
J Clin Pharm Ther; 2004 Dec; 29(6):517-20. PubMed ID: 15584939
[TBL] [Abstract][Full Text] [Related]
27. The use of tissue plasminogen activator infusion to re-establish function of tunneled hemodialysis catheters.
Dowling K; Sansivero G; Stainken B; Siskin G; Dolen E; Ahn J; Mitchell N
Nephrol Nurs J; 2004; 31(2):199-200. PubMed ID: 15114800
[TBL] [Abstract][Full Text] [Related]
28. Alteplase licensed for catheter clearance.
Thompson CA
Am J Health Syst Pharm; 2001 Nov; 58(21):2011, 2014. PubMed ID: 11715818
[No Abstract] [Full Text] [Related]
29. Recombinant tissue plasminogen activator for central venous access device occlusion.
Hooke C
J Pediatr Oncol Nurs; 2000 Jul; 17(3):174-8. PubMed ID: 10944865
[TBL] [Abstract][Full Text] [Related]
30. Successful Rescue Utilization of Intraoperative Tissue Plasminogen Activator in the Setting of Massive Thrombosis of Avalon Catheter and Patient in Extremis with Refractory Hypoxemia.
Martin AK; Allen WL; Fritz AV; Diaz-Gomez JL
J Cardiothorac Vasc Anesth; 2018 Oct; 32(5):2278-2281. PubMed ID: 29395819
[No Abstract] [Full Text] [Related]
31. Tissue plasminogen activator can effectively declot peritoneal dialysis catheters.
Sahani MM; Mukhtar KN; Boorgu R; Leehey DJ; Popli S; Ing TS
Am J Kidney Dis; 2000 Sep; 36(3):675. PubMed ID: 10977805
[No Abstract] [Full Text] [Related]
32. Recombinant tissue plasminogen activator infusion for hemodialysis catheter clearance.
Bamgbola OF; del Rio M; Kaskel FJ; Flynn JT
Pediatr Nephrol; 2005 Jul; 20(7):989-93. PubMed ID: 15843999
[TBL] [Abstract][Full Text] [Related]
33. Failure of silver impregnated subcutaneous cuffs to prevent intravascular catheter infections in cancer patients.
Girvent M; Sitges-Serra A
Ann Surg; 1995 Jan; 221(1):115-6. PubMed ID: 7826153
[No Abstract] [Full Text] [Related]
34. Managing vascular access device occlusions, Part. 1.
Hadaway LC
Nursing; 2000 Jul; 30(7):20. PubMed ID: 10983093
[No Abstract] [Full Text] [Related]
35. Alteplase versus urokinase for occluded hemodialysis catheters.
Zacharias JM; Weatherston CP; Spewak CR; Vercaigne LM
Ann Pharmacother; 2003 Jan; 37(1):27-33. PubMed ID: 12503929
[TBL] [Abstract][Full Text] [Related]
36. Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children.
Jacobs BR; Haygood M; Hingl J
J Pediatr; 2001 Oct; 139(4):593-6. PubMed ID: 11598611
[TBL] [Abstract][Full Text] [Related]
37. Does low-dose heparin maintain central venous access device patency?: a comparison of heparin versus saline during a period of heparin shortage.
Jonker MA; Osterby KR; Vermeulen LC; Kleppin SM; Kudsk KA
JPEN J Parenter Enteral Nutr; 2010; 34(4):444-9. PubMed ID: 20631392
[TBL] [Abstract][Full Text] [Related]
38. Nurse's guide to understanding and treating thrombotic occlusion of central venous access devices.
McKnight S
Medsurg Nurs; 2004 Dec; 13(6):377-82. PubMed ID: 15714740
[TBL] [Abstract][Full Text] [Related]
39. Prophylaxis of upper limb deep vein thrombosis in cancer patients with central vein catheter.
Verso M; Agnelli G
Thromb Haemost; 2008 Jul; 100(1):167-8. PubMed ID: 18612558
[No Abstract] [Full Text] [Related]
40. Successful treatment of a catheter-related right atrial thrombosis with recombinant tissue plasminogen activator and heparin.
Cesaro S; Paris M; Corrò R; Svaluto G; Zanon GF; Gamba P; Milanesi O; Messina C; Zanesco L
Support Care Cancer; 2002 Apr; 10(3):253-5. PubMed ID: 11904791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
